NITD-916 NEW
| Price | $328 | $798 | $1090 |
| Package | 1mg | 5mg | 10mg |
| Supply Ability: | 10g |
| Update Time: | 2026-07-14 |
Product Details
| Product Name: NITD-916 | CAS No.: 1614262-83-7 |
| Purity: 99.01% | Supply Ability: 10g |
| Release date: 2026/07/14 |
Product Introduction
Bioactivity
| Name | NITD-916 |
| Description | NITD-916, a 4-hydroxy-2-pyridone derivative, is a mycobacterial enoyl reductase InhA inhibitor (IC50=570 nM) with oral activity and high lipophilicity. Capable of forming a ternary complex with InhA and NADH, blocking fatty acyl substrate binding and inhibiting mycolic acid synthesis, thereby exerting potent anti-tuberculosis effects. |
| In vitro | Methods: The broth microdilution method was used to detect the in vitro activity of NITD-916, with Mycobacterium abscessus standard strains and clinical isolates as test organisms, incubated in CaMHB medium at 30°C for 3–5 days, at concentrations of 1.25×, 10×, and 20× MIC; meanwhile, intracellular bactericidal experiments were performed using THP-1 macrophages with an MOI of 2:1, incubated for 1–3 days. Results: NITD-916 showed low MIC against both smooth and rough type strains, and 10× MIC significantly reduced intracellular bacterial load. [1] Methods: The nutrient starvation model was used to detect the in vitro activity of NITD-916, with Mycobacterium tuberculosis H37Rv as the test organism. Non-replicating bacteria were prepared by starvation culture in PBS for 2 weeks, then NITD-916 (0.14–0.58 μM) was added with a final DMSO concentration of 2%, and continuously incubated for 21 days. CFU was determined by plate counting method. Results: NITD-916 showed time-dependent bactericidal activity, reducing viable bacterial counts by more than 3 log units within 21 days, with no drug-resistant mutant strains growing. [2] |
| In vivo | Methods: An acute pulmonary infection mouse model was used, in which 6-week-old male BALB/c mice were infected intranasally with Mycobacterium abscessus and treated with NITD-916 (100 mg/kg) dissolved in microemulsion preconcentrate by daily oral gavage for 14 consecutive days; control groups received rifabutin, clarithromycin, or blank vehicle. Results: NITD-916 reduced pulmonary bacterial load by 5.6 log?? CFU in mice, with significant improvement in lung lesions and inflammation, showing superior efficacy to clarithromycin and comparable efficacy to rifabutin. [3] Methods: A Mycobacterium tuberculosis-infected mouse model was used to validate the in vivo activity of NITD-916. Drug was administered via oral route in both acute and chronic infection models, with dose and treatment duration following conventional anti-tuberculosis regimens, and vehicle meeting preclinical dosing standards. Results: NITD-916 demonstrated in vivo efficacy comparable to isoniazid, effectively reducing pulmonary bacterial load, with significantly lower resistance incidence than isoniazid, and showed good safety and tolerability. [4] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 15 mg/mL (48.17 mM), Sonication is recommended. |
| Keywords | tuberculosis | NITD-916 |
| Inhibitors Related | Neomycin sulfate | Adipic dihydrazide | Levulinic acid | D(+)-Raffinose pentahydrate | Sulfamethoxazole sodium | Terbinafine hydrochloride | Doxycycline | Hyaluronic acid sodium (MW 20 kDa) | Dimethyl sulfoxide | Sodium diacetate | Sodium bicarbonate | BES |
| Related Compound Libraries | Bioactive Compound Library | Antibiotics Library | Inhibitor Library | Anti-Bacterial Compound Library | Orally Active Compound Library | Bioactive Compounds Library Max | Anti-Infection Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $148.00 |
VIP4Y
|
TargetMol Chemicals Inc.
|
2026-07-15 | |
| $5790.00 |
VIP2Y
|
TargetMol Chemicals Inc.
|
2026-07-21 | |
| $99.00 |
Amikon Limited
|
2019-09-06 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY